BUZZ-Jefferies upgrades Australia's Clarity Pharma to 'buy' after latest trial

Reuters

Dec 17, 2025

** Jefferies upgrades Clarity Pharmaceuticals CU6.AX to 'buy' from 'hold', retains A$5.00 price target** Brokerage says Phase 2 trial data shows co's 64Cu-Sartate in patients with neuroendocrine tumours (NETs) identified more lesions than competition** After CU6's share price performance, we move to 'buy' - Jefferies** All 4 analysts recommend 'buy' or higher with median PT at A$7.70, as per LSEG-compiled data

**YTD, shares down 30%

(Reporting by Nichiket Sunil in Bengaluru)

((Nichiket.Sunil@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2592393461"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2592393461\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2592393461?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-17 03:13","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2592393461","market":"fut","top_or_hot":-1,"title":"BUZZ-Jefferies upgrades Australia's Clarity Pharma to 'buy' after latest trial","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Jefferies upgrades Australia's Clarity Pharma to 'buy' after latest trial</title></head><body><p>** Jefferies upgrades <a href=\"https://laohu8.com/S/CU6.AU\">Clarity Pharmaceuticals</a> <span>CU6.AX</span> to 'buy' from 'hold', retains A$5.00 price target** Brokerage says Phase 2 trial data shows co's 64Cu-Sartate in patients with neuroendocrine tumours (NETs) identified more lesions than competition** After CU6's share price performance, we move to 'buy' - Jefferies** All 4 analysts recommend 'buy' or higher with median PT at A$7.70, as per LSEG-compiled data</p><p>**YTD, shares down 30%</p><p> (Reporting by Nichiket Sunil in Bengaluru)</p><p> ((Nichiket.Sunil@thomsonreuters.com))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-Jefferies upgrades Australia's Clarity Pharma to 'buy' after latest trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-Jefferies upgrades Australia's Clarity Pharma to 'buy' after latest trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-17 03:13</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Jefferies upgrades Australia's Clarity Pharma to 'buy' after latest trial</title></head><body><p>** Jefferies upgrades <a href=\"https://laohu8.com/S/CU6.AU\">Clarity Pharmaceuticals</a> <span>CU6.AX</span> to 'buy' from 'hold', retains A$5.00 price target** Brokerage says Phase 2 trial data shows co's 64Cu-Sartate in patients with neuroendocrine tumours (NETs) identified more lesions than competition** After CU6's share price performance, we move to 'buy' - Jefferies** All 4 analysts recommend 'buy' or higher with median PT at A$7.70, as per LSEG-compiled data</p><p>**YTD, shares down 30%</p><p> (Reporting by Nichiket Sunil in Bengaluru)</p><p> ((Nichiket.Sunil@thomsonreuters.com))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CU6.AU","symbol_name":"CLARITY PHARMACEUTICALS LTD","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251216:nL6N3XM13C:1","article_id":"2592393461","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2592393461","pubTimestamp":1765912437,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-Jefferies upgrades Australia's Clarity Pharma to 'buy' after latest trial** Jefferies upgrades Clarity Pharmaceuticals CU6.AX to 'buy' from 'hold', retains A$5.00 price target** Brokerage says Phase 2 trial data shows co's 64Cu-Sartate in patients with neuroendocrine tumours  identified more lesions than competition** After CU6's share price performance, we move to 'buy' - Jefferies** All 4 analysts recommend 'buy' or higher with median PT at A$7.70, as per LSEG-compiled data**YTD, shares down 30%  ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CU6.AU":"CLARITY PHARMACEUTICALS LTD","BK7096":"制药"},"translate_title":"BUZZ-Jefferies在最新试验后将澳大利亚Clarity Pharma评级上调至“买入”","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CU6.AU":0.9},"content_text":"BUZZ-Jefferies upgrades Australia's Clarity Pharma to 'buy' after latest trial** Jefferies upgrades Clarity Pharmaceuticals CU6.AX to 'buy' from 'hold', retains A$5.00 price target** Brokerage says Phase 2 trial data shows co's 64Cu-Sartate in patients with neuroendocrine tumours (NETs) identified more lesions than competition** After CU6's share price performance, we move to 'buy' - Jefferies** All 4 analysts recommend 'buy' or higher with median PT at A$7.70, as per LSEG-compiled data**YTD, shares down 30% (Reporting by Nichiket Sunil in Bengaluru) ((Nichiket.Sunil@thomsonreuters.com))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}